



United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/038,284	01/02/2002	Ralf Ehricht	235.022US1	6813	
21186	7590 06/24/2005		EXAMINER		
SCHWEGM	AN, LUNDBERG, WOE	FORMAN, BETTY J			
P.O. BOX 293					
MINNEAPOL	.IS, MN 55402-0938	ART UNIT	PAPER NUMBER		
		1634			
			DATE MAILED: 06/24/2005		

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application	No.	Applicant(s)				
Office Action Summary		10/038,284		EHRICHT ET AL.				
		Examiner		Art Unit				
	·	BJ Forman		1634				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply								
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).								
Status								
1) 🖾 1	Responsive to communication(s) filed on	13 April 2005.						
2a)⊠ ⁻	This action is FINAL . 2b)	This action is nor	n-final.					
3)□ :	Since this application is in condition for allowance except for formal matters, prosecution as to the ments is							
(closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.							
Disposition of Claims								
4)⊠ Claim(s) <u>1-19 and 25-47</u> is/are pending in the application.								
4	4a) Of the above claim(s) is/are withdrawn from consideration.							
	5) Claim(s) is/are allowed.							
	6)⊠ Claim(s) <u>1-19 25-47</u> is/are rejected.							
_	7) Claim(s) is/are objected to.							
8) Claim(s) are subject to restriction and/or election requirement.								
Application	on Papers							
9)☐ The specification is objected to by the Examiner.								
10)☐ The drawing(s) filed on is/are: a)☐ accepted or b)☐ objected to by the Examiner.								
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).								
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).								
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.								
Priority under 35 U.S.C. § 119								
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of:								
1. Certified copies of the priority documents have been received.								
 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage 								
application from the International Bureau (PCT Rule 17.2(a)).								
* See the attached detailed Office action for a list of the certified copies not received.								
Attachment(:	s)							
_ `	of References Cited (PTO-892)	4	Interview Summary (PTO-413)				
2) 🔲 Notice	of Draftsperson's Patent Drawing Review (PTO-94	18)	Paper No(s)/Mail Da	te				
	ation Disclosure Statement(s) (PTO-1449 or PTO/5 No(s)/Mail Date		Other:	atent Application (PTO-152)			

FINAL ACTION

Status of the Claims

1. This action is in response to papers filed 13 April 2005 in which claims 1, 25 and 44-45 were amended and claims 46-47 were added. The amendments have been thoroughly reviewed and entered.

The previous rejections in the Office Action dated 13 October 2004 under 35 U.S.C. 112, second paragraph are withdrawn in view of the amendments.

The previous rejection 35 U.S.C. 112, first paragraph, not reiterated below, are withdrawn in view of the support cited on page 14 of the specification.

The previous rejections under 35 U.S.C. 102(b); 102 (e); and 103(a) are maintained.

Applicant's arguments have been thoroughly reviewed and are discussed below. New grounds for rejection, necessitated by the amendments and new claims, are discussed.

Claims 1-19 and 25-47 are under prosecution.

Comments

reiterated from the previous office action

2. The claims are drawn to a device comprising a chamber body and chamber support placed so as to from a capillary gap between the body and support. The claims contain numerous recitations of adaptations to the device so as to provide functionality to the device e.g. adapted to amplify, characterize, immobilize. However, most of the claims do not define or describe the <u>structural</u> adaptation whereby the functionality is achieved. It is noted that the courts have stated that claims drawn to an apparatus must be distinguished from the prior art in terms of structure rather than function see *In re Danly*, 263 F.2d 844, 847, 120 USPQ 528, 531 (CCPA1959). "[A]pparatus claims cover what a device is, not what a device does."

Hewlett-Packard Co. v. Bausch & Lomb Inc., 909 F.2d 1464, 1469, 15 USPQ2d 1525,1528 (Fed. Cir. 1990) (see MPEP, 2114).

The claims that do not define the structure are given their broadest reasonable interpretation consistent with the claim language and specification. For example, adapted to immobilize is interpreted as encompassing any environment wherein molecules are immobilized or contained (i.e. any indentation, compartment or surface); adapted to characterize is interpreted as encompassing any environment wherein molecule are viewed or tested (i.e. any indentation, compartment or surface); and adapted to amplify is interpreted as encompassing any environment wherein a cell or organism would grow and or multiply (i.e. any indentation, compartment or surface).

Claim Rejections - 35 USC § 112

35 U.S.C. 112: first paragraph

- 3. The following is a quotation of the first paragraph of 35 U.S.C. 112:
 - The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.
- 4. Claims 40 and 44-47 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

The recitation "capillary gap adapted to provide almost simultaneous performance of a chip-based characterization and at least one reprocessing reactions and conditioning reactions"

Art Unit: 1634

is recited in claim 40. However, the specification fails to define or provide any disclosure to support such claim recitation.

The recitation "only the single chamber holds the nucleic acids for both reaction and characterization, and wherein the sample inlet and sample outlet are connected only to the single chamber" is added to Claim 44 (from which Claims 45-47 depend). Applicant has not pointed to any supportive teaching of the newly added limitations and none has been found.

The recitation "the single chamber is free of fluid channels to move the nucleic acids to a subsequent reaction and characterization chamber" is added to Claim 47. Applicant has not pointed to any supportive teaching of the newly added limitations and none has been found.

MPEP 2163.06 notes "If New Matter is added to the claims, the examiner should reject the claims under 35 U.S.C. 112, first paragraph - written description requirement. In re Rasmussen, 650 F.2d 1212, 211 USPQ 323 (CCPA 1981)." MPEP 2163.02 teaches that "Whenever the issue arises, the fundamental factual inquiry is whether a claim defines an invention that is clearly conveyed to those skilled in the art at the time the application was filed...If a claim is amended to include subject matter, limitations, or terminology not present in the application as filed, involving a departure from, addition to, or deletion from the disclosure of the application as filed, the examiner should conclude that the claimed subject matter is not described in that application." MPEP 2163.06 further notes "When an amendment is filed in Reply to an objection or rejection based on 35 U.S.C. 112, first paragraph, a study of the entire application is often necessary to determine whether or not "new matter" is involved. Applicant should therefore specifically point out the support for any amendments made to the disclosure" (emphasis added).

Response to Arguments

5. Applicant points to page 10, lines 1-8, page 24, lines 4-6 and original Claim 19 for support of Claim 40 "the capillary gap is adapted to provide almost simultaneous performance of chip-based characterization...." The passages teach simultaneous hybridization, simultaneous identification of various pathogens and simultaneous reactions. However, none of the cited passages teach or support the claimed **adaptation** of the capillary gap whereby the simultaneous reactions/identifications are provided. Therefore, one of skill in the art would not be appraised of the structural adaptation being claimed. Furthermore, the specification

has been reviewed for a description of the claimed adaptation, but none has been found.

Therefore, the specification does not provide support for Claim 40. The rejection is maintained.

Page 5

Claim Rejections - 35 USC § 102

6. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

- (b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.
- (e) the invention was described in (1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent or (2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effects for purposes of this subsection of an application filed in the United States only if the international application designated the United States and was published under Article 21(2) of such treaty in the English language.
- 7. Claims 1-5, 8-10, 12-15, 17-19, 25-36 and 38-43 are rejected under 35 U.S.C. 102(b) as being anticipated by Lipshutz et al. (U.S. Patent No. 5,856,174, issued 5 January 1999).

Regarding Claim 1, Lipshutz et al disclose a device for duplicating and characterizing nucleic acids, the device comprising, a chamber body containing an optically permeable chip (i.e. glass, Column 14, line 35-Column 15, line 29) having a detection area having an optically permeable zone of detection (i.e. transparent window, Column 19, lines 20-29) adapted to immobilize nucleic acids, peptides or proteins e.g. polymerase enzymes (Column 8, lines 23-42) wherein the chip is placed and sealed on an optically permeable chamber support (i.e. planar glass support, Column 15, lines 9-34) so that a sample chamber having a capillary gap is formed between the chamber support and the detection area (i.e. the reaction chamber is

Art Unit: 1634

manufactured into the surface of a first planar member which is then covered by a second planar member providing a gap between the first and second planar members, Column 15, lines 9-34) wherein the gap (chamber) is provided with amplification and characterization means i.e. temperature control means for thermocycling and pcr amplification whereby nucleic acids are amplified and characterized via amplification (Column 19, lines 1-15 and Column 24, line 34-Column 25, line 41).

Regarding Claim 2, Lipshutz et al disclose the device comprising temperature adjustment means connected to the chamber support and permit rapid temperature control of the gap i.e. provide conditions for PCR amplifications within the chamber (Column 19, lines 1-15 and Column 24, line 34-Column 25, line 41).

Regarding Claim 3, Lipshutz et al disclose the device wherein the temperature adjustment means are situated on the side of the chamber support facing the chamber body (Column 24, lines 34-63 and Fig 2B #128).

Regarding Claim 4, Lipshutz et al disclose the device wherein the optically permeable zone of detection includes detection spots (i.e. transparent window for observation of a "particular analysis", Column 19, lines 20-29) and wherein the temperature adjustment means are configured such that the optical transparency of the chip remains unaffected i.e. the "heater insert" is disposed on the side of the chamber thereby not affecting the transparency of the chip Fig 2B #106/112 (Column 24, lines 34-63 and Fig 2B #128).

Regarding Claim 5, Lipshutz et al disclose the device wherein the temperature adjustment means comprises micro-structured heating elements i.e. nickel-chromium film (Column 24, lines 53-59) and micro-structured temperature sensors (Column 25, lines 7-41).

Regarding Claim 8, Lipshutz et al disclose the device wherein the chamber support and body consist of glass, synthetic material or optically permeable synthetic materials e.g.nylon, Teflon, topaz, polycarbonate, polystyrene, PMMA and/or polymethane, ethyl acrylate (Column 15, lines 26-58).

Art Unit: 1634

Regarding Claim 9, Lipshutz et al disclose the device wherein the chamber support consists of thermally conducting material i.e. the heating/cooling means are embedded within the support which then conducts the heat to the reaction chamber (Column 27, lines 37-47 and Fig. 8 #806).

Regarding Claim 10, Lipshutz et al disclose the device wherein the chip consists of optically permeable materials e.g. glass (Column 15, lines 25-29).

Regarding Claim 12, Lipshutz et al disclose the device further comprising an inlet and an outlet spatially separate from each other i.e. fluid channel #212 is an inlet for reaction chamber #214 and fluid channel #216 is an outlet for reaction chamber #214 (Fig. 3 and Column 16, lines 12-18).

Regarding Claim 13, Lipshutz et al disclose the device wherein the inlet and outlet are arranged unilaterally and are separated by a gas reservoir nose i.e. gas permeable membrane to allow escape of accumulated gas (Column 17, lines 28-38)

Regarding Claim 14, Lipshutz et al disclose the device wherein the chamber body is sealingly and unreleasely connected with the chamber support with an adhesive or welding connection (Column 15, lines 20-29)

Regarding Claim 15, Lipshutz et al disclose the device wherein the detection area is configured in the form of spots onto which nuclei acid probes are immobilized i.e. positionally distinct probes (Column 9, lines 30-35 and Column 9, lines 20-29).

Regarding Claim 17, Lipshutz et al disclose the device wherein the detection area is configured in the form of spots onto which probes in the form or peptides or proteins are immobilized e.g. polymerase enzymes (Column 8, lines 23-42).

Regarding Claim 18, Lipshutz et al disclose the device wherein the capillary gap is adapted to allow characterization by optical detection (i.e. transparent window for observation of a "particular analysis", Column 19, lines 20-29)

Art Unit: 1634

Regarding Claim 19, Lipshutz et al disclose the device is adapted to allow characterization (i.e. transparent window for observation of a "particular analysis", Column 19, lines 20-29). The instantly recited "by a silver precipitation reaction" does not describe or define a structural component of the device. Lipshutz et al teach the device is adapted for characterization via observation through a transparent window, and because the recitation "by a silver precipitation reaction" does not describe or define additional structural components of the device, the device of Lipshutz et al is encompassed by the instantly claimed device.

Regarding Claim 25, Lipshutz et al disclose a device for duplication and characterizing nucleic acids comprising a chamber support, a chamber body on the support and a capillary gap intermediate the support and body, the gap being adapted to act as a single chamber for both the reaction (e.g. hybridization) and characterization (detection) of nucleic acids (e.g. Fig. 7A; Column 15, lines 9-34; and Column 19, lines 1-15 and Column 24, line 34-Column 25, line 41).

Lipshutz et al teach their device comprises the chamber, support and gap whereby a single chamber is formed for reaction and characterization of nucleic acids. They further teach their device comprises additional reaction chambers. However, a single chamber is formed for hybridization and detection of nucleic acids. Therefore, the device of Lipshutz et al is encompassed by the instant claim.

Regarding Claim 26, Lipshutz et al disclose their device wherein the chamber includes an optically permeable chip (i.e. transparent window, Column 19, lines 20-29).

Regarding Claim 27, Lipshutz et al disclose their detection area includes immobilized probes (Column 8, lines 23-42; Column 9, lines 30-35; and Column 9, lines 20-29).

Regarding Claim 28, Lipshutz et al disclose their immobilized probes include nucleic acids, peptides or proteins (Column 8, lines 23-42; Column 9, lines 30-35; and Column 9, lines 20-29).

Art Unit: 1634

Regarding Claim 29, Lipshutz et al disclose the device wherein the detection area is optically permeable (i.e. transparent window, Column 19, lines 20-29).

Regarding Claim 30, Lipshutz et al disclose the device wherein the capillary gap is temperature adjustable and flow controllable. The claim does not require that the device comprise means for temperature adjustment or flow control of the capillary gap. The claim merely requires that the capillary gap be adjustable and controllable. Lipshutz et al teach the temperature and flow within the gap is controlled (Column 27, line 37-Column 29, line 67). Therefore, Lipshutz et al teach the device as claimed.

Regarding Claim 31, Lipshutz et al disclose the device wherein the heating elements include nickel-chromium resistive heaters (Column 24, lines 53-67).

Regarding Claim 32, Lipshutz et al disclose the device of Claim 1 wherein the temperature adjustment means includes micorstructured sensors (Column 25, lines 7-10).

Regarding Claim 33, Lipshutz et al disclose the device wherein the heating elements include nickel-chromium resistive heaters (Column 24, lines 53-67).

Regarding Claim 34, Lipshutz et al disclose the device of Claim 1 wherein at least one of the chamber support and the chamber body include an optically permeable synthetic materials selected from the group consisting of nylon, Teflon, topaz, polycarbonate, polystyrene, PMMA and polymethane ethyl acrylate (Column 15, line 49-Column 16, line 2).

Regarding Claim 35, Lipshutz et al disclose the device of Claim 1 wherein the chamber includes additional sealing surface adapted to releasable connect to the support (e.g. Column 4, lines 55-58; Column 7, lines 65-67; Column 16, lines 42-45; and Column 23, lines 1-27).

Regarding Claim 36, Lipshutz et al disclose the device of Claim 1 wherein the nucleic acid molecules include DNA or RNA (Column 9, line 30-Column 11, line 57).

Regarding Claim 39, Lipshutz et al disclose the device of Claim 18 wherein the optical detection includes at least one of transmitted-light fluorescence measurement, dark field fluorescence measurement, confocal fluorescence measurement, reflected-light fluorescence

measurement, photometry and differential photometry (Column 12, line 63-Column 13, line 9).

Regarding Claim 40, Lipshutz et al disclose the device of Claim 1 wherein the capillary gap is adapted to provide almost simultaneous performance of characterization and reprocessing or conditioning (i.e. transparent window, Column 19, lines 20-29). The claimed "adapted to provide almost simultaneous performance...." does not define or describe structural components of the device. The transparent window of Lipshutz et al would provide for simultaneous observation and hybridization. However, because the claim recitation does not describe structural limitations of the device, the transparent window of Lipshutz is encompassed by the instantly claimed device.

The courts have stated that claims drawn to an apparatus must be distinguished from the prior art in terms of structure rather than function see *In re Danly*, 263 F.2d 844, 847, 120 USPQ 528, 531 (CCPA1959). "[A]pparatus claims cover what a device is, not what a device does." Hewlett-Packard Co. v. Bausch & Lomb Inc., 909 F.2d 1464, 1469, 15 USPQ2d 1525,1528 (Fed. Cir. 1990) (see MPEP, 2114).

Regarding Claims 41-43, Lipshutz et al disclose the device wherein various reactions are performed within a chamber e.g. pcr, transcription (Column 4, lines 1-45). The instantly claimed functions of the device i.e. pcr, reverse transcription, digestive process do not define or describe structural components of the device and therefore do not further limit the claimed device.

Response to Arguments

8. Applicant argues that Lipshutz teaches a plurality of reaction chambers and therefore does not teach the instantly claimed device comprising a single chamber. The argument has been considered but is not found persuasive. First, the open claim language "comprising" recited in the instant claims encompasses any additional elements taught by Lipshutz. The device of Lipshutz comprises a chamber comprising a chamber body and optically permeable support sealed together to form a capillary gap (i.e. well or cavity space forming the reaction

chamber between the body and support, Column 15, lines 14-17) whereby the gap forms a single reaction chamber. The single chamber of Lipshutz is illustrated (e.g. Fig. 3) as comprising, on a single support, a region for amplification (#210) and a region for analysis (#218), the regions within the chamber are connected via channels (e.g. #212 and #216). The device of Lipshutz comprises regions and channels "arranged in serial geometry" but form a single chamber as claimed (Column 17, line 66-Column 18, line 4).

Applicant further argues that Lipshutz teaches amplification in one chamber followed by characterization in a second chamber but does not teach a capillary gap adapted to amplify and characterize nucleic acids as claimed. The argument has been considered but is not found persuasive because as cited above, Lipshutz specifically a single reaction chamber formed by a chamber body and support whereby a gap is formed providing fluid communication between different regions of the device (Column 15, lines 9-31). Applicant appears to be asserting that amplifying and characterizing of nucleic acids are two mutually exclusive events. However, as cited above, Lipshutz specifically teaches the gap (chamber) is provided with amplification and characterization means i.e. temperature control means for thermocycling and per amplification whereby nucleic acids are amplified and characterized via the amplification within the amplification chamber (Column 19, lines 1-15 and Column 24, line 34-Column 25, line 41). Given another interpretation of Lipshutz, their chamber is a miniature integrated device (Column 3, lines 27-30, Fig. 3) comprising multiple smaller chambers (e.g. #206, 210, 214, 218) wherein the integrated device is a single chamber wherein nucleic acids are amplified and characterized.

Applicant asserts that the device of Claim 1 has a single chamber that performs amplification and characterization in that chamber without additional passages. The assertion is noted, however the exclusion of passages is not a limitation of the rejected claims. Therefore the argument is not commensurate in scope with the claims.

Applicant asserts that Lipshutz does not teach the claimed device wherein the chamber body is sealingly placed to form a capillary gap between the support and detection area of the chip. The argument is not found persuasive because the reference clearly teaches these elements (Column 20, line 37-Column 21, line 18 and Fig. 5A-B).

Applicant asserts that Lipshutz does not teach a capillary gap "of extremely small dimensions". The argument has been considered but is not found persuasive because the claims are not so limited. Therefore the argument is not commensurate in scope with the claims.

Applicant asserts that Lipshutz does not teach the limitations of Claim 3. The argument has been considered but is not found persuasive because as cited above the reference teaches the device wherein the temperature adjustment means are situated on a side of the chamber support facing the chamber body (Column 24, lines 34-63 and Fig 2B #128).

9. Claims 1, 2, 4, 5, 8-10, 12, 14, 15, 17-19, 25-30, 32, 34-36, 39-43 are rejected under 35 U.S.C. 102(e) as being anticipated by Woudenberg et al. (U.S. Patent No. 6,126,899, filed 2 April 1997).

Regarding Claim 1, Woudenberg et al disclose a device comprising a chamber body containing an optically permeable zone of detection (#180, Column 11, lines 11-25 and Fig. 6-9) and an optically permeable support (Column 12, lines 4-10) on which the body is sealingly placed to form a capillary gap (#164) wherein the gap forms a single reaction chamber adapted to amplify and characterize nucleic acids (Column 2, lines 32-46 and Column 3, lines 27-46).

Regarding Claim 2, Woudenberg et al disclose the device further comprising means connected with the chamber for rapid temperature control (Column 3, lines 53-64).

Art Unit: 1634

Regarding Claim 4, Woudenberg et al disclose the device wherein the optically permeable zone includes detection spots (#108 or 168) wherein the temperature means are configured such that transparency of the chip is unaffected i.e. a signal is measured at timed intervals during the reaction which could only happen if the transparency remains unaffected (Column 21, lines 29-35).

Regarding Claim 5, Woudenberg et al disclose the device wherein the temperature adjustment means comprise micro-structured heating elements e.g. resistive tracings (Column 21, lines 47-54).

Regarding Claim 8, Woudenberg et al disclose the device wherein the support and body consist of glass, synthetic material or optically permeable synthetic material (Column 11, lines 13-20).

Regarding Claim 9, Woudenberg et al disclose the device wherein the support consists of a thermally conducting material (Column 11, lines 26-29).

Regarding Claim 10, Woudenberg et al disclose the device wherein the chip consists of glass, quartz or silicon (Column 11, lines 13-30).

Regarding Claim 12, Woudenberg et al disclose the device wherein the body includes an inlet (sample inlet #102/162) and outlet (vacuum port #106/216) spatially separate from each other (Fig. 6/9).

Regarding Claim 14, Woudenberg et al disclose the device wherein the body and support are sealingly and unrealeasably connected by adhesive (Column 12, line 58-Column 13, line 18).

Regarding Claim 15, Woudenberg et al disclose the device wherein the detection area is configured in the form of spots (#108 or 168) having nucleic acid probes immobilized i.e. preloaded reagents (e.g. nucleic acid probes or primes) are dried thereby immobilized to the detection spot (Column 16, lines 8-20 and Column 19, lines 45-Column 20, line 7).

Art Unit: 1634

Regarding Claim 17, Woudenberg et al disclose the device wherein the detection area is configured in the form of spots (#108 or 168) having peptide or proteins i.e. preloaded polymerase (Column 16, lines 13-15).

Regarding Claim 18, Woudenberg et al disclose the device wherein the gap is configured to allow optical or spectroscopy detection (Column 20, lines 10-23).

Regarding Claim 19, Woudenberg et al disclose the device is adapted to allow various forms of detections via optical and non-optical methods (Column 20, lines 10-13). The instantly recited "by a silver precipitation reaction" does not describe or define a structural component of the device. Because the recitation "by a silver precipitation reaction" does not describe or define additional structural components of the device, the device of Woudenberg et al is encompassed by the instantly claimed device.

Regarding Claim 25, Woudenberg et al disclose a device comprising a chamber body (#180, Column 11, lines 11-25 and Fig. 6-9), chamber support (#164, Column 12, lines 4-10) and a capillary gap between the body and support wherein the gap forms a single reaction chamber adapted for reaction and characterization nucleic acids (Column 2, lines 32-46 and Column 3, lines 27-46).

Regarding Claim 26, Woudenberg et al disclose the device wherein the body contains an optically permeable chip (#180, Column 11, lines 11-25; Column 12, lines 4-10; and Fig. 6-9).

Regarding Claim 27, Woudenberg et al disclose the device wherein the detection area includes immobilized probes within the gap i.e. pre-loaded reagents (e.g. nucleic acid probes or primers) are dried thereby immobilized to the detection spot (Column 16, lines 8-20 and Column 19, lines 45-Column 20, line 7).

Regarding Claim 28, Woudenberg et al disclose the device wherein the probes include nucleic acids (Column 16, lines 8-20 and Column 19, lines 45-Column 20, line 7).

Regarding Claim 29, Woudenberg et al disclose the device wherein the detection area is optically permeable (e.g. Column 12, lines 4-10).

Art Unit: 1634

Regarding Claim 30, Woudenberg et al disclose the device wherein the gap is temperature adjustable and flow-controllable (i.e. sample distribution network) (Column 13, lines 19-27 and 54-64).

Regarding Claim 32, Woudenberg et al disclose the device wherein the temperature adjustment includes microstructured temperature sensors i.e. temperature feedback (Column 26, lines 10-13).

Regarding Claim 34, Woudenberg et al disclose the device wherein the optically permeable material is polycarbonate or polystyrene (Column 10, lines 662-65 and Column 11, lines 13-20).

Regarding Claim 35, Woudenberg et al disclose the device further comprising an additional sealing surface i.e. inlet seal (Column 14, lines 56-63).

Regarding Claim 36, Woudenberg et al disclose the device wherein the nucleic acids are DNA or RNA (Column 15, lines 25-38).

Regarding Claim 39, Woudenberg et al disclose the device wherein the optical detection includes at least one of transmitted-light fluorescence measurement, dark field fluorescence measurement, confocal fluorescence measurement, reflected-light fluorescence measurement, photometry and differential photometry (Column 20, lines 13-23).

Regarding Claim 40-43, Woudenberg et al disclose the device wherein characterization (i.e. detection) is performed during reaction (i.e. at selected time points) and therefore, "almost" simultaneously as claimed (Column 21, lines 29-35). Woudenberg et al further teach various reactions are performed within the chamber e.g. PCR, ligation, primer extension and etc (Column 3, lines 28-38). The instantly claimed "adapted to perform" does not define or describe structural elements of the device. Because Woudenberg et al specifically teach the claimed structural elements, because Woudenberg et al teach various reactions performed within the device, and because the instant claims do not define further structural components of the device, Woudenberg et al teach the device as claimed.

Response to Arguments

10. Applicant asserts that Woudenberg et al. do not teach the claimed capillary gap. The argument has been considered but is not found persuasive because the reference teaches the sealed device wherein the upper transparent and lower body of the device are sealingly placed to provide observation through and fluid movement within (Column 10, lines 42-59 and Column 12, line 58-Column 13, line 19).

Applicant asserts that Woudenberg does not teach a detection area adapted for immobilization of nucleic acids. The argument has been considered but is not found persuasive because the reference specifically teaches that the detection chamber is pre-loaded with reagent e.g. probe or primers (Column 15, lines5-Column 16, line 35). The claims merely require the detection area be adapted to immobilize nucleic acids, peptides or proteins. The adaptation is not defined or limited to any specific type of immobilization e.g. functional groups for covalent binding. Therefore, the pre-loaded probes and primer are encompassed by the broadly claimed "adapted for".

Applicant asserts that Woudenberg does not teach the limitations of Claim 4. The argument has been considered but is not found persuasive because as cited above the reference teaches that a signal is measured at timed intervals <u>during the</u> reaction which could only happen if the transparency remains unaffected (Column 21, lines 29-35).

Applicant argues that Woudenberg teaches an array of detection chambers and not detection spots as claimed. The argument has been considered but is not found persuasive because the claimed detection spots are not limited or defined by any structure so as to differentiate from the arrayed spots taught in the reference. Therefore, the reference teaches the spots as broadly claimed.

NEW GROUNDS FOR REJECTION

necessitated the amendments and new claims

11. Claims 44, 45 and 47 are rejected under 35 U.S.C. 102(e) as being anticipated by Northrup et al. (ups 6,521,181, filed 26 December 1996).

Regarding Claim 44, Northrup et al disclose a device for duplicating and characterizing nucleic acids, the device comprising, a chamber body including sample inlet and outlet (#35 & 36) and a capillary gap intermediate the support and body (space within chamber #31), the gap consisting of a single chamber for both reaction and characterization of nucleic acids such that only the single chamber holds nucleic acids and wherein the inlet and outlet are only connected to the single chamber (Column 7, lines 20-44 and Fig. 3, 15 and 16).

Regarding Claim 45, Northrup et al disclose the device wherein the gap includes means for reacting and characterizing the sample (i.e. transparent housing whereby light is directed into the chamber for heating and detecting fluorescence (Column 7, lines 20-44).

Regarding Claim 47, Northrup et al disclose the device wherein the single chamber is free of fluid channels to move nucleic acids to a subsequent reaction and characterization chamber (Column 7, lines 37-44 and Fig. 3).

Claim Rejections - 35 USC § 103

- 12. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:
 - (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

13. Claims 6 and 7 are rejected under 35 U.S.C. 103(a) as being unpatentable over Lipshutz et al (U.S. Patent No. 5,856,174, issued 5 January 1999) or Woudenberg et al (U.S. Patent No. 6,126,899, filed 2 April 1997) in view of McBride et al (U.S. Patent No. (6,296,752, filed 4 June 1999) as defined by Academic Press Dictionary of Science and Technology (Academic Press, San Diego, 1992, page 1768)

Regarding Claims 6 and 7, the devices of Lipshutz et al and Woudenberg et al are discussed above. They do not teach the a quadrupole system comprising electrodes of gold-titanium.

However, electro-osmotic flow provided by gold-titanium electrodes was well known in the art at the time the claimed invention was made as taught by McBride et al who teach that improved electrodes for providing electro-osmotic flow comprise gold and titanium (Column 4, lines 1-16) wherein their electrode device comprises multiple electrodes providing a distribution of magnetic poles (Column 3, lines 34-55). Furthermore, Academic Press Dictionary of Science and Technology defines a distribution of magnetic poles as a quadrupole. Therefore, the multiple electrode device of McBride et al is a quadrupole system as defined by the Academic Press Dictionary.

It would have been obvious to one of ordinary skill in the art at the time the claimed invention was made to apply the multiple gold-titanium electrodes of McBride et al. to the electrodes of Lipshutz et al. or Woudenberg et al. based on the improved teaching of McBride et al. (Column 4, lines 1-16).

Response to Arguments

14. Applicant argues that McBride does not teach the elements missing from and discussed above regarding Lipshutz and therefore the above rejection is improper. The argument has been considered but is not found persuasive for the reasons stated above regarding Lipshutz.

15. Claim 11 is rejected under 35 U.S.C. 103(a) as being unpatentable over Lipshutz et al (U.S. Patent No. 5,856,174, issued 5 January 1999) or Woudenberg et al (U.S. Patent No. 6,126,899, filed 2 April 1997) in view of Atwood et al (U.S. Patent No. 5,475,610, filed 20 April 1992).

Regarding Claim 11, the devices of Lipshutz et al and Woudenberg et al are discussed above. They do not teach the reaction chamber comprises a conical recess. However, it was well known in the art at the time the claimed invention was made that the preferred surface for PCR reactions comprise conical recesses as taught by Atwood et al (Column 12, lines 28-47). Atwood et al further teach that conical recesses provide very tight temperature control for all samples and within each sample throughout the PCR cycles (Column 12, lines 40-47). It would have been obvious to one of ordinary skill in the art at the time the claimed invention was made to apply the conical recess of Atwood et al to the PCR reaction chamber of Lipshutz et al or Woudenberg et al thereby providing means for very tight temperature control for the expected benefit of controlling temperature of each sample throughout the PCR cycles as taught by Atwood et al (Column 12, lines 40-47).

Response to Arguments

16. Applicant argues that Atwood does not teach the elements missing from and discussed above regarding Lipshutz and therefore the above rejection is improper. The argument has been considered but is not found persuasive for the reasons stated above regarding Lipshutz.

17. Claim 16, 17 and 37 are rejected under 35 U.S.C. 103(a) as being unpatentable over . Lipshutz et al (U.S. Patent No. 5,856,174, issued 5 January 1999) or Woudenberg et al (U.S.

Patent No. 6,126,899, filed 2 April 1997) in view of Fodor et al (U.S. Patent No. 5,744,101, issued 28 April 1998).

Regarding Claims 16 and 37, the devices of Lipshutz et al and Woudenberg et al are discussed above. They do not specifically teach the probes are immobilized through spacers. However, Fodor et al do teach their probes are immobilized through spacers (i.e. linkers) and they teach a motivation to immobilize through spacers i.e. degree of probe-target binding is dependent on the presence of spacers (Column 18, lines 42-67). It would have been obvious to one of ordinary skill in the art at the time the claimed invention was made to apply the spacers of Fodor et al to the immobilized probes of Lipshutz et al or Woudenberg et al to thereby maximize probe-target binding as taught by Fodor et al (Column 18, lines 39-41).

Regarding Claim 17, Lipshutz et al teach the device wherein proteins are immobilized (Column 8, lines 39-42) but they do not teach the detection area comprises probes in the form of spots. However, detection areas (arrays) comprising spots of protein probes were well known in the art at the time the claimed invention was made as taught by Fodor et al who teach the peptide array provide a tool for high-density peptide-specific antibody recognition (Column 8, line 61-Column 9, line 30). It would have been obvious to one of ordinary skill in the art at the time the claimed invention was made to apply the peptide probes of Fodor et al to the detection area of Lipshutz et al to thereby provide for high-density antibody screening for the expected benefits of determining relative binding affinity between a plurality of peptides simultaneously as taught by Fodor et al (Column 2, lines 44-49).

Regarding Claim 38, Lipshutz et al teach the device wherein the proteins included receptor molecules e.g. antibodies (Column 8, lines 36-42).

Response to Arguments

18. Applicant argues that Fodor does not teach the elements missing from and discussed above regarding Lipshutz and therefore the above rejection is improper. The argument has been considered but is not found persuasive for the reasons stated above regarding Lipshutz.

19. Claim 46 is rejected under 35 U.S.C. 103(a) as being unpatentable over Northrup et al (ups 6,521,181, filed 26 December 1996) in view of Woudenberg et al (U.S. Patent No. 6,126,899, filed 2 April 1997).

Regarding Claim 46, Northrup et al disclose a device for duplicating and characterizing nucleic acids, the device comprising, a chamber body including sample inlet and outlet (#35 & 36) and a capillary gap intermediate the support and body (space within chamber #31), the gap consisting of a single chamber for both reaction and characterization of nucleic acids such that only the single chamber holds nucleic acids and wherein the inlet and outlet are only connected to the single chamber (Column 7, lines 20-44 and Fig. 3, 15 and 16) but they do not teach the device includes a gas reservoir. However, Woudenberg et al teach a similar device comprising a gas reservoir (i.e. gas source) for receiving bubbles from the capillary gap whereby the degree of sample filling and detection is enhanced (Column 9, lines 49-64). It would have been obvious to one of ordinary skill in the art at the time the claimed invention was made to apply the gas reservoir of Woudneberg et al to the device of Northrup for the expected benefit of removing bubbles from the chamber to thereby enhance the degree of sample filling and detection as taught by Woudenberg et al (Column 9, liens 58-64). While they do not teach the reservoir provides thermal insulation, the recited functionality does not describe or define a structural component of the device.

The courts have stated that claims drawn to an apparatus must be distinguished from the prior art in terms of structure rather than function see *In re Danly*, 263 F.2d 844, 847, 120 USPQ 528, 531 (CCPA1959). "[A]pparatus claims cover what a device is, not what a device does." Hewlett-Packard Co. v. Bausch & Lomb Inc., 909 F.2d 1464, 1469, 15 USPQ2d 1525,1528 (Fed. Cir. 1990) (see MPEP, 2114).

20. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Conclusion

21. No claim is allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to BJ Forman whose telephone number is (571) 272-0741. The examiner can normally be reached on 6:00 TO 3:30.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Jones can be reached on (571) 272-0745. The fax phone number for the organization where this application or proceeding is assigned is (571) 273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to (571) 272-0547.

Patent applicants with problems or questions regarding electronic images that can be viewed in the Patent Application Information Retrieval system (PAIR) can now contact the USPTO's Patent Electronic Business Center (Patent EBC) for assistance. Representatives are available to answer your questions daily from 6 am to midnight (EST). The toll free number is (866) 217-9197. When calling please have your application serial or patent number, the type of document you are having an image problem with, the number of pages and the specific nature of the problem. The Patent Electronic Business Center will notify applicants of the resolution of the problem within 5-7 business days. Applicants can also check PAIR to confirm that the problem has been corrected. The USPTO's Patent Electronic Business Center is a complete service center supporting all patent business on the Internet. The USPTO's PAIR system provides Internet-based access to patent application status and history information. It also enables applicants to view the scanned images of their own application file folder(s) as well as general patent information available to the public.

For all other customer support, please call the USPTO Call Center (UCC) at 800-786-9199.

BJ Forman, Ph.D. Primary Examiner Art Unit: 1634

June 21, 2005